Description

Simple

A medication used to prevent respiratory distress syndrome in young children.

Clinical

A lung surfactant for the prophylaxis of respiratory distress syndrome in high-risk infants.

Overview

Calfactant is a sterile, non-pyrogenic lung surfactant intended for intratracheal instillation. It is an off-white suspension of an extract of natural surfactant from calf lungs suspended in 0.9% saline. Each milliliter of calfactant contains 35mg of phospholipids (including 26 mg phosphatidylcholine of which 16 mg is disaturated phosphatidylcholine) and 0.65mg of proteins including surfactant-associated proteins B and C.

Calfactant is approved for use in the United States of America. It is used to prevent or treat respiratory distress syndrome in premature infants with lung surfactant deficiency. Calfactant has been shown to decrease the incidence of respiratory distress syndrome, mortality due to respiratory distress syndrome, and air leaks associated with respiratory distress syndrome in clinical trials. It adsorbs to the air:fluid interface in the lungs and works to reduce surface tension, in a manner similar to endogenous pulmonary surfactant.

Pharmacology

Indication

Calfactant is indicated for prophylaxis therapy to prevent respiratory distress syndrome (RDS) in premature infants Read more

Pharmacodynamic

Information currently not available.

Mechanism of action

Pulmonary surfactant is an endogenous substance produced in the lungs that functions to decrease surface tension at the air:fluid interface on the alveolar surface. In premature infants with pulmonary surfactant deficiency, surface tension can increase to the point where sections of lung collapse an... Read more

Absorption

Calfactant is administered directly to the lung lumen surface where it acts. No human studies on absorption have been completed.

Protein binding

Information currently not available.

Volume of distribution

No human studies on the distribution of calfactant have been performed.

Clearance

No human studies on the metabolism and elimination of calfactant have been performed.

Half life

Half time clearance from the lung lumen was reported as 12 hours in a study of normal rabbits.

Route of elimination

No human studies on elimination of calfactant have been completed.

Toxicity

Carcinogenesis and animal reproduction studies have not been performed with calfactant. A single mutagenicity study produced a negative Ames assay. Overdose with calfactant has not yet been reported, but it is recommended that in the case of an overdose ventilation should be supported until all exce... Read more

Adverse Effects

Contraindications

  • Hypersensitivity:
    • false
  • Regions: US
  • Patient Conditions:
      • Name: None
      • Drugbank Id: DBCOND0107411

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Calfactant
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
Acebutolol
Acebutolol may increase the bradycardic activities of Calfactant.
Agmatine
Calfactant may increase the bradycardic activities of Agmatine.
Alfentanil
Alfentanil may increase the bradycardic activities of Calfactant.
Alprenolol
Alprenolol may increase the bradycardic activities of Calfactant.
Amiodarone
Amiodarone may increase the bradycardic activities of Calfactant.
Amlodipine
Amlodipine may increase the bradycardic activities of Calfactant.
Anisodamine
Calfactant may increase the bradycardic activities of Anisodamine.
Aranidipine
Calfactant may increase the bradycardic activities of Aranidipine.
Arotinolol
Calfactant may increase the bradycardic activities of Arotinolol.
Atenolol
Atenolol may increase the bradycardic activities of Calfactant.
Azelnidipine
Calfactant may increase the bradycardic activities of Azelnidipine.
Barnidipine
Calfactant may increase the bradycardic activities of Barnidipine.
Befunolol
Calfactant may increase the bradycardic activities of Befunolol.
Bencyclane
Calfactant may increase the bradycardic activities of Bencyclane.
Bendroflumethiazide
Bendroflumethiazide may increase the bradycardic activities of Calfactant.
Benidipine
Calfactant may increase the bradycardic activities of Benidipine.
Bepridil
Bepridil may increase the bradycardic activities of Calfactant.
Beractant
Calfactant may increase the bradycardic activities of Beractant.
Betaxolol
Betaxolol may increase the bradycardic activities of Calfactant.
Bevantolol
Bevantolol may increase the bradycardic activities of Calfactant.
9 References
  1. 1 . Willson D: Calfactant. Expert Opin Pharmacother. 2001 Sep;2(9):1479-93.PubMed: 11585026
  2. 2 . Bloom BT, Clark RH: Comparison of Infasurf (calfactant) and Survanta (beractant) in the prevention and treatment of respiratory distress syndrome. Pediatrics. 2005 Aug;116(2):392-9.PubMed: 16061594
  3. 3 . Willson DF, Thomas NJ, Markovitz BP, Bauman LA, DiCarlo JV, Pon S, Jacobs BR, Jefferson LS, Conaway MR, Egan EA: Effect of exogenous surfactant (calfactant) in pediatric acute lung injury: a randomized controlled trial. JAMA. 2005 Jan 26;293(4):470-6.PubMed: 15671432
  4. 4 . Attar MA, Becker MA, Dechert RE, Donn SM: Immediate changes in lung compliance following natural surfactant administration in premature infants with respiratory distress syndrome: a controlled trial. J Perinatol. 2004 Oct;24(10):626-30.PubMed: 15201857
  5. 5 . Nguyen TN, Cunsolo SM, Gal P, Ransom JL: Infasurf and curosurf: theoretical and practical considerations with new surfactants. J Pediatr Pharmacol Ther. 2003 Apr;8(2):97-114. doi: 10.5863/1551-6776-8.2.97.PubMed: 23300398
  6. 6 . Willson DF, Zaritsky A, Bauman LA, Dockery K, James RL, Conrad D, Craft H, Novotny WE, Egan EA, Dalton H: Instillation of calf lung surfactant extract (calfactant) is beneficial in pediatric acute hypoxemic respiratory failure. Members of the Mid-Atlantic Pediatric Critical Care Network. Crit Care Med. 1999 Jan;27(1):188-95.PubMed: 9934915
  7. 7 . Logan JW, Moya FR: Animal-derived surfactants for the treatment and prevention of neonatal respiratory distress syndrome: summary of clinical trials. Ther Clin Risk Manag. 2009 Feb;5(1):251-60. Epub 2009 Mar 26.PubMed: 19436610
  8. 8 . Willson DF, Truwit JD, Conaway MR, Traul CS, Egan EE: The Adult Calfactant in Acute Respiratory Distress Syndrome Trial. Chest. 2015 Aug;148(2):356-64. doi: 10.1378/chest.14-1139.PubMed: 25855884
  9. 9 . McPherson C, Gal P, Ransom JL, Carlos RQ, Dimaguila MA, Smith M, Davonzo C, Wimmer JE Jr: Indomethacin pharmacodynamics are altered by surfactant: a possible challenge to current indomethacin dosing guidelines created before surfactant availability. Pediatr Cardiol. 2010 May;31(4):505-10. doi: 10.1007/s00246-009-9628-6. Epub 2010 Jan 10.PubMed: 20063159